Isomorphic Labs Advances AI-Designed Cancer Drug Toward Human Trials
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
Isomorphic Labs has a broad pipeline of AI-designed medicines heading toward clinical trials, and one compound already has FDA clearance to enter human testing. On January 28, 2026, the FDA cleared ISM8969 for human clinical trials, making it one of the first drugs designed by AI to reach that threshold.
Drug discovery has historically been a game of enormous waste. A compound enters preclinical testing, survives animal studies, clears regulatory review for a Phase 1 trial, and still has roughly a one-in-ten chance of making it to approval. The average timeline runs twelve to fifteen years. The average cost exceeds $2 billion.
Isomorphic Labs, the AI drug design company spun out of Google DeepMind in 2021, is betting that all of those numbers are wrong, and that the right AI models can compress each stage of that process by factors that make pharmaceutical incumbents uncomfortable. The company said its drug design engine, formally called IsoDDE and detailed in a company announcement in February 2026, represents a substantial evolution beyond AlphaFold 3. IsoDDE is not just predicting how molecules fold — it is designing new ones from scratch, targeting disease mechanisms that traditional medicinal chemistry has struggled to address.
The company said ISM8969 is unusual not just because AI designed it, but because the AI identified a molecular interaction that human researchers had not been prioritizing. Isomorphic has confirmed its initial clinical pipeline focuses on oncology candidates. Partnerships with Eli Lilly and Novartis, reported to total $3 billion in deal value, provide validation and clinical infrastructure to run trials.
The company closed a $600 million financing round in March 2025, providing the runway to advance programs into human studies without depending entirely on partnership economics. It also signaled that its original target of putting AI-designed drugs in clinical trials by the end of 2025 had been pushed back by roughly twelve months, with the revised goal being the end of 2026.